(SHL) Siemens Healthineers - Ratings and Ratios

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures, and markets a comprehensive range of diagnostic and therapeutic products and services. The companys diverse portfolio is organized into four business segments: Imaging, Diagnostics, Varian, and Advanced Therapies, catering to various healthcare needs worldwide. The Imaging segment is a prominent player in the medical imaging market, offering cutting-edge technologies such as magnetic resonance imaging and computed tomography systems.

The companys Diagnostics segment is a significant provider of in-vitro diagnostic products and services, supporting laboratory and point-of-care diagnostics. Siemens Healthineers AG has a strong presence in the oncology market through its Varian segment, delivering cancer care technologies and solutions to hospitals and clinics. The Advanced Therapies segment focuses on image-guided minimally invasive treatments, serving various medical specialties like cardiology and interventional radiology.

Siemens Healthineers AG provides a broad range of technical customer services, including maintenance, repair, and training, as well as digital healthcare consulting and managed departmental services. The company was spun off from Siemens Aktiengesellschaft in 2017 and is headquartered in Forchheim, Germany. With a global footprint, Siemens Healthineers AG is poised to capitalize on the growing demand for medical technology and healthcare services.

Analyzing the companys , we observe a market capitalization of 55.2 billion EUR, with a P/E ratio of 26.46 and a forward P/E of 18.35, indicating a relatively high valuation. However, the RoE of 11.16% suggests a decent return on equity. Considering the , the stock is currently trading at 45.79 EUR, below its SMA20 and SMA50 levels, but significantly lower than its 52-week high of 57.04 EUR. The ATR of 0.97 EUR (2.12%) indicates moderate volatility.

Based on the available data, a forecast for Siemens Healthineers AG can be derived. Given the companys diversified product portfolio and global presence, we can expect steady revenue growth. However, the high P/E ratio and current price below its short-term moving averages may indicate a potential correction or consolidation phase. A possible price target could be around 50-52 EUR, based on the SMA200 level and expected earnings growth. Nevertheless, this forecast is subject to various market and economic factors, and actual performance may vary.